Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL122550 | 0.96 | ALDH1A1 (0.37) | ALDH1A1HSD17B10 | |
| SCHEMBL15467307 | 0.96 | ALDH1A1 (0.37) | ALDH1A1HSD17B10 | |
| SCHEMBL14534464 | 0.92 | — | — | |
| SCHEMBL22037 | 0.92 | — | — | |
| SCHEMBL1047397 | 0.84 | — | — | |
| SCHEMBL1054620 | 0.84 | — | — | |
| SCHEMBL427201 | 0.83 | — | — | |
| SCHEMBL6323393 | 0.80 | ALDH1A1 (0.41) | ALDH1A1HSD17B10 | |
| SCHEMBL18107133 | 0.80 | — | — | |
| SCHEMBL7120115 | 0.80 | ALDH1A1 (0.41) | ALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4016656-A1 | ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND DIAGNOSTIC COMPOSITION INCLUDING THE ORGANOMETALLIC COMPOUND | Samsung Electronics Co., Ltd. (KR) | 2022-06-22 | — | — | EP | disclosed |
| EP-2675870-B1 | PRODUCTION OF HYDROCARBONS FROM COPYROLYSIS OF PLASTIC AND TYRE MATERIAL WITH MICROWAVE HEATING | TECHWAVE S R L (IT) | 2019-09-11 | — | — | EP | disclosed |
| US-8143254-B2 | Methods for modulating ion channels | CORNELL RESEARCH FOUNDATION, INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-7847119-B2 | Drug conjugates | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2010-12-07 | — | — | US | disclosed |
| US-20090005386-A1 | Methods for Modulating Ion Channels | PACE UNIVERSITY | 2009-01-01 | — | — | US | disclosed |
| US-20080139815-A1 | DRUG CONJUGATES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-06-12 | — | — | US | disclosed |
| US-7282590-B2 | Selectively target tumor cells with highly potent cytotoxic drugs at a drug release rate that is effective for the destruction and/or inhibition of tumor cells | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2007-10-16 | — | — | US | disclosed |
| EP-1718335-A2 | DRUG CONJUGATES | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2006-11-08 | — | — | EP | disclosed |
| US-20060222869-A1 | Electropen lithography | ENERGY, UNITED STATES DEPARTMENT | 2006-10-05 | — | — | US | disclosed |
| WO-2006089168-A2 | METHODS FOR MODULATING ION CHANNELS | CORNELL RESEARCH FOUNDATION, INC. (US) | 2006-08-24 | — | — | WO | disclosed |
| US-20050232928-A1 | Drug conjugates | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-10-20 | — | — | US | disclosed |
| WO-2005079398-A2 | DRUG CONJUGATES | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2005-09-01 | — | — | WO | disclosed |
| WO-2005042509-A1 | 7-`(7-ALKOXY)-CHROM-3-EN-6-YL!-HEPTATRIENOIC ACID AND 7-`(3ALKOXY)-5,6-DIHYDRONAPHTHALEN-2-YL!-HEPTATRIENOIC ACID DERIVATIVES MODULATORS | ALLERGAN, INC. (US) | 2005-05-12 | — | — | WO | disclosed |
| US-20050096380-A1 | 7-[(7-ALKOXY)-CHROM-3-EN-6-YL]-HEPTATRIENOIC ACID AND 7-[(3-ALKOXY)-5,6-DIHYDRONAPHTHALEN-2-YL]-HEPTATRIENOIC ACID DERIVATIVES HAVING SERUM GLUCOSE REDUCING ACTIVITY | ALLERGAN, INC. | 2005-05-05 | — | — | US | disclosed |
| US-6887896-B1 | 7-[(7-Alkoxy)-chrom-3-en-6-yl]-heptatrienoic acid and 7-[(3-alkoxy)-5,6-dihydronaphthalen-2-yl]-heptatrienoic acid derivatives having serum glucose reducing activity | ALLERGAN, INC. (US) | 2005-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050232928-A1 | Drug conjugates | RXRB, NR0B1, RXRA | ALDH1A1 399/4885HSD17B10 462/4885 |
| US-20050096380-A1 | 7-[(7-ALKOXY)-CHROM-3-EN-6-YL]-HEPTATRIENOIC ACID AND 7-[(3-ALKOXY)-5,6-DIHYDRONAPHTHALEN-2-YL]-HEPTATRIENOIC ACID DERIVATIVES HAVING SERUM GLUCOSE REDUCING ACTIVITY | TPO, THRA, FABP6 | ALDH1A1 529/4885HSD17B10 131/4885 |
| US-20090005386-A1 | Methods for Modulating Ion Channels | KCNJ5, KCNN4, TRPV1 | ALDH1A1 1871/4885HSD17B10 4566/4885 |
| US-20080139815-A1 | DRUG CONJUGATES | RXRB, NR0B1, RXRA | ALDH1A1 414/4885HSD17B10 464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.